Image - Barts and The London logo and link to home page Image - divider Image - divider
  Image - Wolfson Institute of Preventive Medicine title and link to Institute home page
Images - preventive medicine, people
  Image - Centre for Cancer Prevention title and link to CCP homepage
Attila T Lorincz PhD
Professor of Molecular Epidemiology

Professor Lorincz is a molecular biologist recognized for his research in human diagnostics and the natural history of human papillomavirus infections. He invented and disseminated the Hybrid Capture (HC) series of HPV tests. These nucleic acid amplification tests are generally recognized as the gold standard in routine HPV screening worldwide, with more that 10 million tests conducted annually. As a prelude to the development of HC2 he cloned and characterized several clinically important HPV types, provided a clearer understanding of the natural history of HPV infection, and pioneered large clinical studies that revealed key evidence of the association of HPV with cervical cancer. More than 35 US and international patents concerning novel HPV types and novel assay systems have been awarded for his work. He has authored more than 150 original peer-reviewed research papers and books on diverse topics in epidemiology and the basic molecular mechanisms of carcinogenesis. He was primary author of a paper chosen by the American College of Obstetrics and Gynecology as a “classic”. This paper was the first to show key differences in the relative risks of HPV types and led to the low, medium and high risk classification system of HPV cancer risk. The paper is the most frequently cited article to appear in the journal Obstetrics & Gynecology to date. Prof Lorincz was the recipient of the 1994 AVDA achievement award from the American Venereal Disease Association for outstanding contributions to the field of STD research. His current research interests are the epigenetics of prostate, breast and cervical cancers

Selected publications

  1. Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, Rush BB, Gravitt PE, Schussler JE, Schiffman M. 2002. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 360:228-9.
  2. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M. 2003. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95:46-52.
  3. Salmeron J, Lazcano-Ponce E, Lorincz A, Hernandez M, Hernandez P, Leyva A, Uribe M, Manzanares H, Antunez A, Carmona E, Ronnett BM, Sherman ME, Bishai D, Ferris D, Flores Y, Yunes E, Shah KV. 2003. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 14:505-12.
  4. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. 2005. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst  97:1072-9.
  5. Darwin LH, Cullen AP, Arthur PM, Long CD, Smith KR, Girdner JL, Hook EW III, Quinn TC, Lorincz AT. 2002. Comparison of Digene Hybrid Capture 2 and conventional culture for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in cervical specimens. J Clin Microbiol 40:641-644.
  6. Lorincz AT, Richart RM. 2003. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch Pathol Lab Med 127:959-68.
  7. Sellors JW, Karwalajtys TL, Kaczorowski J, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A, for the Survey of HPV in Ontario Women (SHOW) Group. 2003. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 168:421-5.
  8. Castle PE, Schiffman M, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Wacholder S, Lorincz AT. 2005. Semi-quantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer. Cancer Epidemiol Biomarkers Prev 14:1311-4.
  9. Hesselink AT, Bulkmans NWJ, Berkhof J, Lorincz AT, Meijer CJLM, Snijders PJF. 2006. Cross-sectional comparison of an automated Hybrid Capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol  44:3680-5.
  10. Khanna N, Mishra SI, Tian G, Tan M, Arnold S, Lee C, Ramachandran S, Bell L, Baquet CR, Lorincz A. 2007. HPV detection in self-collected vaginal specimens and matched physician-collected cervical specimens. Int J Gynecol Cancer 17:615-22.
by CCP Website Manager © Queen Mary, University of London 2011
Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London, Charterhouse Square, London EC1M 6BQ Tel: 020 7882 3850  Fax: 020 7882 3890